Private company

DUSA Pharmaceuticals

American pharmaceutical company

DUSA Pharmaceuticals, Inc. was an American pharmaceutical company specializing in dermatological products and treatments. It was founded in 1991 by Canadian dermatologist and pharmaceutical executive D. Geoffrey Shulman, who served as the company's chairman, president and chief executive officer. The company developed Levulan photodynamic therapy, a treatment using aminolevulinic acid.³ It is headquartered in Wilmington, Massachusetts.¹ Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersWilmington, Massachusetts¹
Listed onNasdaq¹
Incorporated inNJ⁴
Business address25 Upton Drive, Wilmington, Ma 01887⁴
Filer categoryLarge Accelerated⁴

See how the biggest companies compare on our leaderboards

What it owns

What DUSA Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$1.6M⁶ Dec 31, 2011	$1.6M⁶ Dec 31, 2010	+1.2%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$24.4M⁶ Dec 31, 2011	$8.9M⁶ Dec 31, 2010	+174.9%
Marketable securities, current	$3.8M⁶ Dec 31, 2011	$10.8M⁶ Dec 31, 2010	−64.8%

Inventory

Item	Latest	A year before	Change
Inventory, total	$2.8M⁶ Dec 31, 2011	$2.0M⁶ Dec 31, 2010	+37.9%

The story

In the first quarter of 2006, DUSA acquired Sirius Laboratories in a transaction valued at approximately $30 million. Sirius was a privately held specialty pharmaceutical company founded by dermatologist Joel E. Bernstein in 2000. It developed treatments for conditions including acne vulgaris and rosacea.

In June 2007, Robert F. Doman was elected chief executive officer. Shulman remained chairman of the board and assumed the position of chief strategic officer. In April 2008, DUSA announced that Shulman's role was expected to change because of a serious illness. His employment agreement was terminated in December 2008 and replaced by a part-time consulting arrangement, with company filings citing his health.

In 2012, Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharmaceutical, acquired DUSA.

From Wikipedia’s article on DUSA Pharmaceuticals, shared under CC BY-SA 4.0.⁵

Leadership

Who has led DUSA Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

2010201520202025

Chief executive officerRobert F. Doman May 12, 2008 to Dec 20, 2012⁷
Chief executive officerD. Geoffrey Shulman Mar 20, 2006 to Mar 21, 2007⁸
ChairD. Geoffrey Shulman Mar 20, 2006 to May 13, 2008⁸
PresidentRobert F. Doman Mar 20, 2006 to Dec 20, 2012⁹
Chief financial officerRichard Christopher Mar 29, 2006 to Dec 20, 2012¹⁰
Chief operating officerRobert F. Doman Mar 20, 2006 to Nov 14, 2007⁹

Board members and other officers (18)

Vice President, OperationsMark Carota Mar 29, 2006 to Dec 20, 2012¹¹
VP Marketing & SalesPaul A. Sowyrda Mar 29, 2006 to Mar 29, 2006¹²
VP, Regulatory Affairs & IPScott L. Lundahl Mar 29, 2006 to Dec 20, 2012¹³
VP, Sc. Aff & CMOStuart L. Marcus Mar 29, 2006 to Dec 20, 2012¹⁴
Exec. VP Sales and MarketingWilliam F. Odell Apr 5, 2006 to Dec 20, 2012¹⁵
Vice President, ControllerMichael Todisco Sep 19, 2006 to Dec 20, 2012¹⁶
Board memberAlfred Altomari Aug 2, 2010 to Dec 20, 2012¹⁷
Board memberDavid M. Wurzer Aug 2, 2010 to Dec 20, 2012¹⁸
Board memberPaul J. Hondros Aug 4, 2010 to Dec 20, 2012¹⁹
Board memberAlexander W. Casdin Feb 3, 2009 to Dec 20, 2012²⁰
Board memberMarvin E. Lesser Jun 11, 2009 to Jul 1, 2010²¹
Board memberRobert F. Doman Mar 21, 2007 to Dec 20, 2012²²
Board memberNeal Stuart Penneys Mar 14, 2006 to Aug 8, 2006²³
Board memberDavid M. Bartash Jul 5, 2006 to Dec 20, 2012²⁴
Board memberJay M. Haft Jul 5, 2006 to Dec 20, 2012²⁵
Board memberJohn H. Abeles Jul 5, 2006 to Jul 1, 2010²⁶
Board memberMagnus Moliteus Jul 5, 2006 to Dec 20, 2012²⁷
Board memberRichard C. Lufkin Jul 5, 2006 to Jul 1, 2010²⁸

Timeline

May 12, 2008New chief executive Robert F. Doman becomes CEO⁷
Mar 20, 2006New chief executive D. Geoffrey Shulman becomes CEO⁸

SEC filer profile

How DUSA Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARDUSA PHARMACEUTICALS INC²
CIK0000879993
Employer ID (EIN)22-3103129²
Filer statusLarge accelerated²
Incorporated inNew Jersey²
Fiscal year endsDecember 31²
Industry code (SIC)2834 Pharmaceutical Preparations²
Business address25 Upton Drive, Wilmington, MA 01887²
Phone9786577500²
Shares outstanding25,027,683 as of Nov 7, 2012²⁹
Public float$149.7M as of Jun 30, 2011⁶
On EDGAR sinceAug 12, 1996²
Filings755 in all: 4 (267), 8-K (137), SC 13G/A (59), 10-Q (49), CT ORDER (31), SC 13G (26), 3 (18), 10-K (16)²
All 43 form types
DEF 14A (16), S-8 POS (16), 4/A (13), EFFECT (11), POS AM (8), S-3 (6), S-3/A (6), S-8 (6), SC 13D (6), SC 13D/A (6), SC 14D9/A (6), SC TO-T/A (6), 8-K/A (5), 3/A (4), ARS (4), UPLOAD (4), 10-K/A (3), CORRESP (3), REGDEX (3), 424B3 (2), 8-A12G (2), S-3MEF (2), SC14D9C (2), 10-Q/A (1), 15-12B (1), 25-NSE (1), 424B7 (1), 8-A12B (1), DEFA14A (1), DFAN14A (1), FWP (1), PRE 14A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)
Latest filingsAnnual report (10-K) Mar 6, 2012
Quarterly report (10-Q) Nov 9, 2012
Proxy statement (DEF 14A) Apr 18, 2012
Latest 8-K (8-K) Dec 21, 2012

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataDUSA Pharmaceuticals on Wikidata
2
SEC EDGARDUSA Pharmaceuticals filings on SEC EDGAR
3
WikipediaDUSA Pharmaceuticals on Wikipedia
4
SEC EDGARDUSA Pharmaceuticals filings on SEC EDGAR
5
WikipediaDUSA Pharmaceuticals on Wikipedia (revision used)
6
SEC EDGARDUSA Pharmaceuticals 10-K for fiscal 2011
7
SEC EDGARRobert F. Doman, Chief executive officer
8
SEC EDGARD. Geoffrey Shulman, Chief executive officer
9
SEC EDGARRobert F. Doman, President
10
SEC EDGARRichard Christopher, Chief financial officer
11
SEC EDGARMark Carota, Vice President, Operations
12
SEC EDGARPaul A. Sowyrda, VP Marketing & Sales
13
SEC EDGARScott L. Lundahl, VP, Regulatory Affairs & IP
14
SEC EDGARStuart L. Marcus, VP, Sc. Aff & CMO
15
SEC EDGARWilliam F. Odell, Exec. VP Sales and Marketing
16
SEC EDGARMichael Todisco, Vice President, Controller
17
SEC EDGARAlfred Altomari, Board member
18
SEC EDGARDavid M. Wurzer, Board member
19
SEC EDGARPaul J. Hondros, Board member
20
SEC EDGARAlexander W. Casdin, Board member
21
SEC EDGARMarvin E. Lesser, Board member
22
SEC EDGARRobert F. Doman, Board member
23
SEC EDGARNeal Stuart Penneys, Board member
24
SEC EDGARDavid M. Bartash, Board member
25
SEC EDGARJay M. Haft, Board member
26
SEC EDGARJohn H. Abeles, Board member
27
SEC EDGARMagnus Moliteus, Board member
28
SEC EDGARRichard C. Lufkin, Board member
29
SEC EDGARDUSA Pharmaceuticals 10-Q filed Nov 9, 2012: shares outstanding

Overview

What it owns

Property and equipment

Investments

Inventory

The story

Leadership

Chief executive

Chair

President

Chief financial officer

Chief operating officer

Timeline

SEC filer profile

Links

Sources